Preparing for the Unexpected: The Pivotal Role of Social and Behavioral Sciences in Trials of Biomedical HIV Prevention Interventions

Abstract:A range of efficacies have been reported for biomedical HIV prevention interventions, including antiretroviral treatment, male circumcision, preexposure prophylaxis, microbicides, and preventive vaccines. This range of efficacies probably results from the influence of multiple inputs and processes during trials, including the strength and target of the intervention, host factors, target population characteristics, level of HIV exposure, and intervention dose. Expertise in social and behavioral sciences, in conjunction with basic science, clinical research, epidemiology, biostatistics, and community, is needed to understand the influence of these inputs and processes on intervention efficacy, improve trial design and implementation, and enable interpretation of trial results. In particular, social and behavioral sciences provide the means for investigating and identifying populations suitable for recruitment into and retention in trials and for developing and improving measures of HIV exposure and intervention dose, all within the larger sociocultural context. Integration of social and behavioral sciences early in idea generation and study design is imperative for the successful conduct of biomedical trials and for ensuring optimal data collection approaches necessary for the interpretation of findings, particularly in cases of unexpected results.

[1]  Scott Rose,et al.  Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[2]  David V Glidden,et al.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.

[3]  A. Kamali,et al.  HIV Incidence and Risk Factors for Acquisition in HIV Discordant Couples in Masaka, Uganda: An HIV Vaccine Preparedness Study , 2011, PloS one.

[4]  Stephen Moses,et al.  Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial , 2007, The Lancet.

[5]  Devan V Mehrotra,et al.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.

[6]  C. Gravlee.  How race becomes biology: embodiment of social inequality. , 2009, American journal of physical anthropology.

[7]  Michael Rayment,et al.  Prevention of HIV-1 infection with early antiretroviral therapy , 2012, Journal of Family Planning and Reproductive Health Care.

[8]  L. van Damme,et al.  Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention , 2012, AIDS.

[9]  James D. Campbell,et al.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. , 2012, The New England journal of medicine.

[10]  Lynn Morris,et al.  Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women , 2010, Science.

[11]  Kenneth F Schulz,et al.  Blinding in randomised trials: hiding who got what , 2002, The Lancet.

[12]  J. Justman,et al.  Adherence and Acceptability in MTN 001: A Randomized Cross-Over Trial of Daily Oral and Topical Tenofovir for HIV Prevention in Women , 2013, AIDS and Behavior.

[13]  S. Kapiga,et al.  The Value of Site Preparedness Studies for Future Implementation of Phase 2/IIb/III HIV Prevention Trials: Experience From the HPTN 055 Study , 2008, Journal of acquired immune deficiency syndromes.

[14]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[15]  N. Padian,et al.  Invited commentary: condom effectiveness-will prostate-specific antigen shed new light on this perplexing problem? , 2003, American journal of epidemiology.

[16]  Punnee Pitisuttithum,et al.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. , 2006, The Journal of infectious diseases.

[17]  N. Astone,et al.  Welfare Realities: From Rhetoric to Reform , 1994 .

[18]  P. Feldblum,et al.  SAVVY Vaginal Gel (C31G) for Prevention of HIV Infection: A Randomized Controlled Trial in Nigeria , 2008, PloS one.

[19]  Kenneth F Schulz,et al.  Generation of allocation sequences in randomised trials: chance, not choice , 2002, The Lancet.

[20]  C. Mauck.  Biomarkers of semen exposure. , 2009, Sexually transmitted diseases.

[21]  S. Buchbinder,et al.  Sexual Risk Behaviors, Circumcision Status, and Preexisting Immunity to Adenovirus Type 5 Among Men Who Have Sex With Men Participating in a Randomized HIV-1 Vaccine Efficacy Trial: Step Study , 2012, Journal of acquired immune deficiency syndromes.

[22]  Kenneth H Mayer,et al.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. , 2005, The Journal of infectious diseases.

[23]  J. Garbarino.  The ecology of human development: Experiments by nature and design: by Urie Bronfenbrenner Cambridge, Mass.: Harvard University Press, 1979, 330 + p. , 1980 .

[24]  Oliver Laeyendecker,et al.  Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial , 2007, The Lancet.

[25]  D. Orr,et al.  Validity of Self‐Reported Sexual Behaviors in Adolescent Women Using Biomarker Outcomes , 1997, Sexually transmitted diseases.

[26]  S. Self,et al.  Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. , 2001, American journal of epidemiology.

[27]  S. Buchbinder,et al.  HIV Sexual Risk Behavior Over 36 Months of Follow-Up in the World's First HIV Vaccine Efficacy Trial , 2005, Journal of acquired immune deficiency syndromes.

[28]  L. Myer,et al.  Adolescent and adult participation in an HIV vaccine trial preparedness cohort in South Africa. , 2008, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[29]  Jaranit Kaewkungwal,et al.  Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. , 2012, The Lancet. Infectious diseases.

[30]  R. Roddy,et al.  SAVVY® (C31G) Gel for Prevention of HIV infection in Women: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Ghana , 2007, PloS one.

[31]  E. Blair,et al.  Cognitive Processes Used by Survey Respondents to Answer Behavioral Frequency Questions , 1987 .

[32]  P. Heagerty,et al.  Readiness of high‐risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States , 1998, AIDS.

[33]  Katrien Fransen,et al.  Preexposure prophylaxis for HIV infection among African women. , 2012, The New England journal of medicine.

[34]  H. Meissner,et al.  Conceptual framework for behavioral and social science in HIV vaccine clinical research. , 2011, Vaccine.

[35]  S. Vermund,et al.  HIV Incidence Rates and Risk Factors for Urban Women in Zambia: Preparing for a Microbicide Clinical Trial , 2009, Sexually transmitted diseases.

[36]  Nneka Emenyonu,et al.  Real-Time Adherence Monitoring for HIV Antiretroviral Therapy , 2010, AIDS and Behavior.

[37]  M. Irkec,et al.  Juvenile xanthogranuloma of the corneal limbus: report of two cases and review of the literature. , 2008, Cornea.

[38]  M N Hochmeister,et al.  Evaluation of prostate-specific antigen (PSA) membrane test assays for the forensic identification of seminal fluid. , 1999, Journal of forensic sciences.

[39]  Emmanuel Lagarde,et al.  Randomized, Controlled Intervention Trial of Male Circumcision for Reduction of HIV Infection Risk: The ANRS 1265 Trial , 2005, PLoS medicine.

[40]  S. Buchbinder,et al.  The HVTN Protocol 903 Vaccine Preparedness Study: Lessons Learned in Preparation for HIV Vaccine Efficacy Trials , 2008, Journal of acquired immune deficiency syndromes.

[41]  E. Vittinghoff,et al.  Determinants of Enrollment in a Preventive HIV Vaccine Trial: Hypothetical Versus Actual Willingness and Barriers to Participation , 2004, Journal of acquired immune deficiency syndromes.

[42]  James P. Hughes,et al.  Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. , 2010, The New England journal of medicine.

[43]  Patrick Heagerty,et al.  Randomized, Controlled Evaluation of a Prototype Informed Consent Process for HIV Vaccine Efficacy Trials , 2003, Journal of acquired immune deficiency syndromes.